PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?

Poly adenosine diphosphate-ribose polymerase inhibitors (PARPi) represent an effective therapeutic strategy for cancer patients harboring germline and somatic aberrations in DNA damage repair (DDR) genes. BRCA1/2 mutations occur at 1–7% across biliary tract cancers (BTCs), but a broader spectrum of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricci, Angela Dalia, Rizzo, Alessandro, Bonucci, Chiara, Tober, Nastassja, Palloni, Andrea, Mollica, Veronica, Maggio, Ilaria, Deserti, Marzia, Tavolari, Simona, Brandi, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555445/
https://www.ncbi.nlm.nih.gov/pubmed/32878011
http://dx.doi.org/10.3390/medicines7090054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555445/
https://www.ncbi.nlm.nih.gov/pubmed/32878011
http://dx.doi.org/10.3390/medicines7090054

Ejemplares similares